Tag: Kite

Home / Established Year

Gilead-Lifescinces
, , , , , ,

Kite completes acquisition of Tmunity

Press Release Feb 2023: - Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech compan..

, , , ,

Tecartus granted European marketing authorization for treatment of relapsed or refractory acute lymphoblastic leukemia

Sept 2022: The European Commission (EC) has authorized Kite's CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and older with relapsed or refractory (r/r) B-cell precurs..

, , ,

CAR NK therapy has an effective rate of 73%

Immunotherapy in treatment of cancerCancer CAR-NK therapy has an effective rate of 73%, and is being recruited in domestic clinical trials.Immunotherapy has revolutionized the way cancer is treated. Cancer immunotherapy is divide..

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟